Back to Search
Start Over
Inhibitory Effect of Cudratrixanthone U on RANKL-Induced Osteoclast Differentiation and Function in Macrophages and BMM Cells
- Source :
- Frontiers in Pharmacology, Frontiers in Pharmacology, Vol 11 (2020)
- Publication Year :
- 2020
- Publisher :
- Frontiers Media S.A., 2020.
-
Abstract
- Cudratrixanthone U (CTU) is a prenylated xanthone compound isolated from Maclura tricuspidata Bureau (Moraceae). Prenylated xanthones have been reported to exhibit a variety of biological activities. However, the effects of prenylated xanthone on osteoclast differentiation and function are still unclear. Excessive bone resorption by osteoclasts is considered a major cause of diseases such as osteoporosis. Accordingly, suppression of excessive osteoclast formation and function is one of strategies for treating osteoclast related bone diseases. In this study, CTU inhibited osteoclast differentiation and function in RAW264.7 macrophages and BMM cells induced by receptor activator of nuclear factor-κB ligand (RANKL). CTU regulated the formation of TRAF6-TAK1 complex in RANKL-induced RAW264.7 macrophages and BMM cells. Osteoclast-specific genes including those encoding matrix metallopeptidase 9 (MMP-9), dendritic cell-specific transmembrane proteins (DC-STAMP), cathepsin K (CTSK) and chemokine CC motif ligand 4 (CCL4) play an important role in bone resorption and migration, and were effectively regulated by CTU. These results suggest that CTU is a potential therapeutic agent in osteoporosis.
- Subjects :
- 0301 basic medicine
musculoskeletal diseases
Chemokine
CCL4
Bone resorption
03 medical and health sciences
0302 clinical medicine
Osteoclast
TAK-1
medicine
Cathepsin K
Pharmacology (medical)
Receptor
Original Research
Pharmacology
biology
Chemistry
lcsh:RM1-950
RANKL
Transmembrane protein
Cell biology
030104 developmental biology
medicine.anatomical_structure
lcsh:Therapeutics. Pharmacology
030220 oncology & carcinogenesis
Cudratrixanthone U
osteoclast
biology.protein
TRAF6
Subjects
Details
- Language :
- English
- ISSN :
- 16639812
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Frontiers in Pharmacology
- Accession number :
- edsair.doi.dedup.....25ff7b6482c32d5f52c9cade5e6c261a